𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Studies in man with cold-recombinant influenza virus (h1n1) live vaccines

✍ Scribed by P. Reeve; Batia Gerendas; A. Moritz E. Liehl; C.Kunz H. Hofmann; H. F. Maassab

Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
505 KB
Volume
6
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Two cold‐recombinant influenza A (H1N1) viruses were tested in several groups of human volunteers. Only minor clinical symptoms were seen and no febrile reactions occurred. With serologically primed individuals virus shedding was low, but a high proportion showed rises in serum antibody levels after vaccination and mean titres were high. With serologically unprimed volunteers shedding was high, about 75% yielding viruses but only at low titres and for a short duration. No revertant viruses were found and there was no evidence of transmission to potentially susceptible individuals housed in close contact to the vaccinees.

Serum antibody responses with unprimed volunteers were, however, low. Only about one half showed increases in serum antibody titres after vaccination and mean titres were low. Nevertheless, challenge with live attenuated virus indicated a high degree of protection based on virological evidence of infection.

πŸ“œ SIMILAR VOLUMES

Studies in man with a cold-recombinant l
Studies in man with a cold-recombinant live influenza b virus vaccine
✍ P. Reeve; M. Pibermann; H. Bachmayer; E. Liehl; A. Moritz; U. Ganzinger; H. Hofm πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 399 KB

## Abstract A cold recombinant live influenza B virus vaccine was tested in man. In comparison to a placebo, reactogenicity attributable to virus infection was slight or moderate. No revertant viruses were shed, and there was no evidence of transmission to the placebo group who were housed in close

A placebo-controlled dose response study
A placebo-controlled dose response study of the reactogenicity and immunogenicity of a live cold-recombinant influenza B virus vaccine in healthy volunteers
✍ Dr. U. Ganzinger; H. Bachmayer; E. Liehl; J. J. Martindale; F. Hamilton; Dr. E. πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 498 KB

A live cold-recombinant influenza B virus vaccine (RB77) was given intranasally in a placebo-controlled, double blind study to volunteers in dosages of 10(7.9) EID50/ml, 10(7.25) EID50/ml, 10(5.7) EID50/ml. The tolerability, safety, and immunogenicity of the vaccine were investigated. No revertant v

Viral load in patients infected with pan
Viral load in patients infected with pandemic H1N1 2009 influenza A virus
✍ Kelvin K.W. To; Kwok-Hung Chan; Iris W.S. Li; Tak-Yin Tsang; Herman Tse; Jasper πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 1 views

Viral shedding profile of infections caused by the pandemic H1N1 2009 influenza A virus has not been reported. The aim of this study was to determine the viral load in different body sites. Viral loads of pandemic H1N1 virus in respiratory specimens, stool, urine, and serum were determined by quanti

Safety of influenza and H1N1 vaccination
Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance
✍ Eitan Auriel; Keren Regev; Amir Dori; Arnon Karni πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 59 KB

## Abstract Myasthenia gravis (MG) exacerbations may be triggered by infections.In the winter of 2009/2010, the Israeli Ministry of Health recommended that each individual with a chronic condition be vaccinated against both the seasonal influenza and the H1N1 virus. We examined vaccination practice